Through timely company announcements, media releases, events and presentations, Genmab discloses and informs all our stakeholders of key events throughout the year.

Who we are

Read about Genmab's purpose, core values and key accomplishments

Learn more
Turning insights into medicine

See the results of innovation that is rooted in science

Explore the pipeline
Innovation for the future

We are developing next-generation technologies

See our technologies

Jan 15, 2021 at 8:18 PM CET Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis	Download
Jan 13, 2021 at 3:21 PM CET Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie	Download
Jan 6, 2021 at 4:16 PM CET Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference	Download
Jan 5, 2021 at 2:27 AM CET Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
Jan 4, 2021 at 8:00 PM CET Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer	Download

Genmab News